First implants of Edwards' Sapien valve:
This article was originally published in Clinica
The first three patients have been treated in a US-based feasibility study of Edwards Lifesciences' Sapien bovine pericardial heart valve. The study will assess the use of the device in a congenital condition where the valve between the right ventricle and the pulmonary artery does not work. The procedure involves the Sapien valve being compressed onto a balloon, threaded through the patient's circulatory system from the leg using the RetroFlex transfemoral delivery system and deployed across the patient's pulmonary valve. The valve replacement is accomplished as a "beating heart" procedure, without requiring cardiopulmonary bypass or an open-chest incision, Irvine, California-based Edwards said.
You may also be interested in...
Assessment work also isn’t slowing down, the new and generic drug office directors said in an interview, but approval data offers a note of concern.
Abbott is launching a second test to detect COVID-19. The diagnostics giant announced on 27 March the release of a rapid, point-of-care test that can deliver results within five minutes.
President Trump on 27 March finally pulled the trigger on using his powers under the Defense Production Act, forcing General Motors Co. to manufacture medical ventilators. The only thing is, GM is already doing that.